Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (9310)	3/21/1999 2:25:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Kindly go back to the past (past posts I mean), and find that meningitis is not the same as meningococcemia, mortality in septic shock is in the 20% to 60% range, posts 8220, 8235 (Spain), posts 7565, 7560 (Ducth) 8599 (meta-analysis), 8216 (France), and 8364 (UK). Peritoneal Ventilation? nobody will fill my belly with gas, it is already full of it. Anyway that should be a poor country, Extracorporeal Membrane Oxygenation and Dyalisis plus heat filtration could accomplish all this without extra gas in the bowels. My tail (my calculations)new version: Total of 400 subjects (take it easy). Two arms (george must be please)and double stratification according to Glasgow scores. 1.Low Glasgow Score: N 100 placebo, mortality 20% = 20 deceased N 100 Bpi treated, mortality 8% = 8 deceased 2.High Glasgow score: N 100 placebo, mortality 40% = 40 deceased N 100 Bpi treated, mortality 15% = 15 deceased Total mortality = 83 New company Headquarters La Havana, no taxes, only Cigars for profits.

To: StockDoc who wrote (9310)	3/21/1999 4:00:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

StockDoc, one will need 20,000 patients, to prove a 10% improvement in the Bpi arm if one assumes a 10% mortality. 10% improvement means: placebo 10%, bpi 9% (1% is the 10% improvement of 10%).

To: StockDoc who wrote (9310)	3/21/1999 7:32:00 PM
From: Robert S.	Read Replies (3) \| Respond to of 17367

StockDoc... By the way, what's the thinking on this board about the apparent efficacy of protein C, antithrombin III and, maybe, activated protein C (Baxter, Genzyme, and Eli Lilly) in bacterial sepsis? I too follow with interest the potential therapeutic treatments you listed; the abstract below illustrates the promising potential: Intensive Care Med 1998 Jul;24(7):663-72 Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U Clinical Research Department, Centeon Pharma GmbH, Marburg, Germany. bernd.eisele@solvay.com OBJECTIVES: To evaluate the safety and potential efficacy of antithrombin III (AT III) in reducing mortality in patients with severe sepsis. DESIGN: Prospective, randomized, placebo-controlled, double-blind, phase II, multicenter, multinational clinical trial. SETTING: Seven academic medical center intensive care units (ICU) in Belgium, Denmark, the Netherlands, Norway and Sweden. PATIENTS: 42 patients with severe sepsis who received standard supportive care and antimicrobial therapy, in addition to the administration of AT III or placebo. INTERVENTIONS: Patients received either an intravenous loading dose of 3000 IU AT III followed by a maintenance dose of 1500 IU every 12 h for 5 days or equivalent amounts of placebo. MEASUREMENTS AND RESULTS: All patients were evaluated for safety and for 30-day all-cause mortality. CONCLUSIONS: The administration of AT III was safe and well-tolerated. It was followed by a 39 % reduction in 30-day all-cause mortality (NS). The reduction in mortality was accompanied by a considerably shorter stay in the ICU. Patients treated with AT III exhibited a better performance in overall severity of illness and organ failure scores (Acute Physiology and Chronic Health Evaluation II, multiple organ failure, organ system failure), which was noticeable soon after initiation of treatment. Patients treated with AT III demonstrated a better resolution of pre-existing organ failures and a lower incidence of new organ failures during the observation period. A meta-analysis comprising this and two other double-blind, placebo-controlled trials with AT III with a total of 122 patients suffering from severe sepsis confirms the positive trend. The results of the meta-analysis demonstrate a 22.9 % reduction in 30-day all-cause mortality in patients treated with AT III. Although still too small to be confirmative, the meta-analysis clearly points to the fact that a sufficiently powered phase III trial is warranted to prove whether AT III has a beneficial role in the treatment of severe sepsis. Publication Types: Clinical trial Clinical trial, phase ii Meta-analysis Multicenter study Randomized controlled trial Comments: Comment in: Intensive Care Med 1998 Jul;24(7):649-50 PMID: 9722035, UI: 98387490